Brain health company Angelini Pharma has announced a strategic collaboration with biotechnology company Quiver Bioscience to discover and advance novel therapeutics to genetic epilepsies. 

The collaboration, which also includes a licensing agreement, brings together Quiver’s drug discovery capabilities, data assets and AI models with Angelini Pharma’s expertise in brain health and epilepsy drug development. 

Under the terms of the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term.  

Quiver is also eligible to receive additional milestones payments of up to $120 million and additional royalties upon Angelini’s election of drug targets identified through the collaboration. 

“The prospects of our collaboration with Quiver Bioscience are very promising,” said Rafal Kaminski, Chief Scientific Officer at Angelini Pharma.  

”The aim is to generate novel scientific insights on a scale and richness that has been unprecedented in this area of research. By applying cutting-edge technologies and advanced data analytics approaches, including AI, this partnership will generate a unique data set to inform the development of novel therapies in the future.” 

“We’re excited to embark on this collaboration with the excellent team at Angelini Pharma,” added Graham T Dempsey, Co-founder and Chief Executive Officer at Quiver Bioscience.  

“Together we are pursuing a novel approach uniquely enabled by Quiver’s technology platform. By leveraging altered electrophysiology in response to genetic perturbations as the core neuronal classifier and integrating paired multi-modal data, we aim to link functional phenotypes with the underlying molecular drivers.  

“We look forward to translating this science into new medicines for a disease area in urgent need of innovation.”